Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) - Yahoo Finance

H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX)  Yahoo Finance

H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) - Yahoo Finance

Click here to get full coverage on There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump - simplywall.st

There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump  simplywall.st

There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump - simplywall.st

Click here to get full coverage on How does LXRX generate profit in a changing economy - Expert Picks Updates Backed By Experts - jammulinksnews.com

How does LXRX generate profit in a changing economy - Expert Picks Updates Backed By Experts  jammulinksnews.com

How does LXRX generate profit in a changing economy - Expert Picks Updates Backed By Experts - jammulinksnews.com

Click here to get full coverage on Lexicon Pharmaceuticals Schedules Pre-Market Q2 Earnings Release, 8:30 AM ET Conference Call - Stock Titan

Lexicon Pharmaceuticals Schedules Pre-Market Q2 Earnings Release, 8:30 AM ET Conference Call  Stock Titan

Lexicon Pharmaceuticals Schedules Pre-Market Q2 Earnings Release, 8:30 AM ET Conference Call - Stock Titan

Click here to get full coverage on Why LXRX stock attracts strong analyst attention - Fast Return Equity Trade Forecast Points to Small Caps - beatles.ru

Why LXRX stock attracts strong analyst attention - Fast Return Equity Trade Forecast Points to Small Caps  beatles.ru

Why LXRX stock attracts strong analyst attention - Fast Return Equity Trade Forecast Points to Small Caps - beatles.ru

Click here to get full coverage on Lexicon Pharmaceuticals (LXRX) Soars 16.74% on Technical Signals - AInvest

Lexicon Pharmaceuticals (LXRX) Soars 16.74% on Technical Signals  AInvest

Lexicon Pharmaceuticals (LXRX) Soars 16.74% on Technical Signals - AInvest

Click here to get full coverage on Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap touched US$389m last week, benefiting both private equity firms who own 48% as well as institutions - simplywall.st

Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap touched US$389m last week, benefiting both private equity firms who own 48% as well as institutions  simplywall.st

Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap touched US$389m last week, benefiting both private equity firms who own 48% as well as institutions - simplywall.st

Click here to get full coverage on Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance

Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...  Yahoo Finance

Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance

Click here to get full coverage on When is LXRX stock expected to show significant growth - Chart Pattern Ideas For Fast Growth - jammulinksnews.com

When is LXRX stock expected to show significant growth - Chart Pattern Ideas For Fast Growth  jammulinksnews.com

When is LXRX stock expected to show significant growth - Chart Pattern Ideas For Fast Growth - jammulinksnews.com

Click here to get full coverage on New Clinical Data Shows Lexicon's Diabetes Drug Effective Across All Kidney Function Levels - ADA Conference - Stock Titan

New Clinical Data Shows Lexicon's Diabetes Drug Effective Across All Kidney Function Levels - ADA Conference  Stock Titan

New Clinical Data Shows Lexicon's Diabetes Drug Effective Across All Kidney Function Levels - ADA Conference - Stock Titan

Click here to get full coverage on Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates  Yahoo Finance

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates  simplywall.st

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st

Click here to get full coverage on What is LXRX company’s growth strategy - Achieve breakthrough profits with smart strategies - jammulinksnews.com

What is LXRX company’s growth strategy - Achieve breakthrough profits with smart strategies  jammulinksnews.com

What is LXRX company’s growth strategy - Achieve breakthrough profits with smart strategies - jammulinksnews.com

Click here to get full coverage on LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? - Yahoo Finance

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?  Yahoo Finance

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? - Yahoo Finance

Click here to get full coverage on Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts - simplywall.st

Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts  simplywall.st

Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts - simplywall.st

Click here to get full coverage on What catalysts could drive LXRX stock higher in 2025 - Discover undervalued stocks before they soar - jammulinksnews.com

What catalysts could drive LXRX stock higher in 2025 - Discover undervalued stocks before they soar  jammulinksnews.com

What catalysts could drive LXRX stock higher in 2025 - Discover undervalued stocks before they soar - jammulinksnews.com

Click here to get full coverage on Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...  Yahoo Finance

Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Click here to get full coverage on Lexicon Pharmaceuticals Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13 - Stock Titan

Lexicon Pharmaceuticals Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13  Stock Titan

Lexicon Pharmaceuticals Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13 - Stock Titan

Click here to get full coverage on Lexicon Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation (NASDAQ:LXRX) - Seeking Alpha

Lexicon Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation (NASDAQ:LXRX)  Seeking Alpha

Lexicon Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation (NASDAQ:LXRX) - Seeking Alpha

Click here to get full coverage on Lexicon Pharmaceuticals Regains Nasdaq Compliance - TipRanks

Lexicon Pharmaceuticals Regains Nasdaq Compliance  TipRanks

Lexicon Pharmaceuticals Regains Nasdaq Compliance - TipRanks

Click here to get full coverage on Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential - Insider Monkey

Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential  Insider Monkey

Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential - Insider Monkey

Click here to get full coverage on Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates  Yahoo Finance

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension - TipRanks

Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension  TipRanks

Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension - TipRanks

Click here to get full coverage on When is LXRX stock expected to show significant growth - Entry Signal Data Feed With Low Risk - jammulinksnews.com

When is LXRX stock expected to show significant growth - Entry Signal Data Feed With Low Risk  jammulinksnews.com

When is LXRX stock expected to show significant growth - Entry Signal Data Feed With Low Risk - jammulinksnews.com

Click here to get full coverage on Is LXRX a growth stock or a value stock - Market Forecast Insights For 2025 - jammulinksnews.com

Is LXRX a growth stock or a value stock - Market Forecast Insights For 2025  jammulinksnews.com

Is LXRX a growth stock or a value stock - Market Forecast Insights For 2025 - jammulinksnews.com

Click here to get full coverage on Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan

Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal  Stock Titan

Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan

Click here to get full coverage on What drives LXRX stock price - Free Investment Community - jammulinksnews.com

What drives LXRX stock price - Free Investment Community  jammulinksnews.com

What drives LXRX stock price - Free Investment Community - jammulinksnews.com

Click here to get full coverage on Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Yahoo Finance

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...  Yahoo Finance

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Yahoo Finance

Click here to get full coverage on Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) - Seeking Alpha

Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)  Seeking Alpha

Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) - Seeking Alpha

Click here to get full coverage on Lexicon Pharmaceuticals faces potential Nasdaq delisting - Investing.com

Lexicon Pharmaceuticals faces potential Nasdaq delisting  Investing.com

Lexicon Pharmaceuticals faces potential Nasdaq delisting - Investing.com

Click here to get full coverage on Revolutionary Non-Opioid Drug Could Help 100M People Suffering from Diabetic Nerve Pain - Stock Titan

Revolutionary Non-Opioid Drug Could Help 100M People Suffering from Diabetic Nerve Pain  Stock Titan

Revolutionary Non-Opioid Drug Could Help 100M People Suffering from Diabetic Nerve Pain - Stock Titan

Click here to get full coverage on Can Lexicon's 38x Revenue Growth and Pain Drug Success Transform Its Future? - Stock Titan

Can Lexicon's 38x Revenue Growth and Pain Drug Success Transform Its Future?  Stock Titan

Can Lexicon's 38x Revenue Growth and Pain Drug Success Transform Its Future? - Stock Titan

Click here to get full coverage on Breakthrough: Sotagliflozin Cuts Dangerous Low Blood Sugar Events in Type 1 Diabetes Patients - Stock Titan

Breakthrough: Sotagliflozin Cuts Dangerous Low Blood Sugar Events in Type 1 Diabetes Patients  Stock Titan

Breakthrough: Sotagliflozin Cuts Dangerous Low Blood Sugar Events in Type 1 Diabetes Patients - Stock Titan

Click here to get full coverage on Lexicon Pharmaceuticals: A High-Potential Biotech Play in the Diabetes Space - AInvest

Lexicon Pharmaceuticals: A High-Potential Biotech Play in the Diabetes Space  AInvest

Lexicon Pharmaceuticals: A High-Potential Biotech Play in the Diabetes Space - AInvest

Click here to get full coverage on Lexicon Pharmaceuticals Holds Annual Stockholder Meeting - TipRanks

Lexicon Pharmaceuticals Holds Annual Stockholder Meeting  TipRanks

Lexicon Pharmaceuticals Holds Annual Stockholder Meeting - TipRanks

Click here to get full coverage on Lexicon Pharmaceuticals' Earnings Surprise: A Catalyst for Revaluation - AInvest

Lexicon Pharmaceuticals' Earnings Surprise: A Catalyst for Revaluation  AInvest

Lexicon Pharmaceuticals' Earnings Surprise: A Catalyst for Revaluation - AInvest

Click here to get full coverage on What are the latest earnings results for LXRX - Exceptional earning trajectories - jammulinksnews.com

What are the latest earnings results for LXRX - Exceptional earning trajectories  jammulinksnews.com

What are the latest earnings results for LXRX - Exceptional earning trajectories - jammulinksnews.com

Click here to get full coverage on The Woodlands-based company strikes obesity-drug license deal worth up to $1B - KHOU

The Woodlands-based company strikes obesity-drug license deal worth up to $1B  KHOU

The Woodlands-based company strikes obesity-drug license deal worth up to $1B - KHOU

Click here to get full coverage on Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Manila Times

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement  The Manila Times

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Manila Times

Click here to get full coverage on Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com

Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal By Investing.com  Investing.com

Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com

Click here to get full coverage on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - Insider Monkey

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript  Insider Monkey

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals - Nasdaq

What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals  Nasdaq

What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals - Nasdaq

Click here to get full coverage on Lexicon Pharma Cuts 60% of Workforce, Saves $140M Amid FDA Setback for Zynquista - Stock Titan

Lexicon Pharma Cuts 60% of Workforce, Saves $140M Amid FDA Setback for Zynquista  Stock Titan

Lexicon Pharma Cuts 60% of Workforce, Saves $140M Amid FDA Setback for Zynquista - Stock Titan

Click here to get full coverage on Lexicon Pharmaceuticals (LXRX) Soars 4.70% on Positive Earnings - AInvest

Lexicon Pharmaceuticals (LXRX) Soars 4.70% on Positive Earnings  AInvest

Lexicon Pharmaceuticals (LXRX) Soars 4.70% on Positive Earnings - AInvest

Click here to get full coverage on Can Lexicon's Non-Opioid Pain Drug Break 20-Year Innovation Drought? Phase 2b Results Reveal Path Forward - Stock Titan

Can Lexicon's Non-Opioid Pain Drug Break 20-Year Innovation Drought? Phase 2b Results Reveal Path Forward  Stock Titan

Can Lexicon's Non-Opioid Pain Drug Break 20-Year Innovation Drought? Phase 2b Results Reveal Path Forward - Stock Titan

Click here to get full coverage on Lexicon Pharma (LXRX) Announces Topline Results from Phase 2b PROGRESS Study - StreetInsider

Lexicon Pharma (LXRX) Announces Topline Results from Phase 2b PROGRESS Study  StreetInsider

Lexicon Pharma (LXRX) Announces Topline Results from Phase 2b PROGRESS Study - StreetInsider

Click here to get full coverage on Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 - Investor's Business Daily

Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1  Investor's Business Daily

Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 - Investor's Business Daily

Click here to get full coverage on How strong is LXRX company’s balance sheet - Free Stock Market Mentorship - jammulinksnews.com

How strong is LXRX company’s balance sheet - Free Stock Market Mentorship  jammulinksnews.com

How strong is LXRX company’s balance sheet - Free Stock Market Mentorship - jammulinksnews.com

Click here to get full coverage on How LXRX stock performs during market volatility - Chart Driven High Reward Trading Setup Presented - metal.it

How LXRX stock performs during market volatility - Chart Driven High Reward Trading Setup Presented  metal.it

How LXRX stock performs during market volatility - Chart Driven High Reward Trading Setup Presented - metal.it

Click here to get full coverage on A Preview Of Lexicon Pharmaceuticals's Earnings - Nasdaq

A Preview Of Lexicon Pharmaceuticals's Earnings  Nasdaq

A Preview Of Lexicon Pharmaceuticals's Earnings - Nasdaq

Click here to get full coverage on Lexicon Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com South Africa

Lexicon Pharmaceuticals regains Nasdaq compliance By Investing.com  Investing.com South Africa

Lexicon Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com South Africa

Click here to get full coverage on Painful Week for Private Equity Firms Invested in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After 16% Drop, Institutions Also Suffered Losses - 富途牛牛

Painful Week for Private Equity Firms Invested in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After 16% Drop, Institutions Also Suffered Losses  富途牛牛

Painful Week for Private Equity Firms Invested in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After 16% Drop, Institutions Also Suffered Losses - 富途牛牛

Click here to get full coverage on H.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stock - Investing.com

H.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stock  Investing.com

H.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stock - Investing.com

Click here to get full coverage on LXRX’s Beta Climbs After Market Volatility - Fast Exit and Entry Strategy Guide Offered - metal.it

LXRX’s Beta Climbs After Market Volatility - Fast Exit and Entry Strategy Guide Offered  metal.it

LXRX’s Beta Climbs After Market Volatility - Fast Exit and Entry Strategy Guide Offered - metal.it

Click here to get full coverage on Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ... - Yahoo Finance

Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ...  Yahoo Finance

Lexicon Pharmaceuticals Inc (LXRX)

Price Chart

Key Statistics

Technicals

About LXRX

Latest News

H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) - Yahoo Finance

There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump - simplywall.st

How does LXRX generate profit in a changing economy - Expert Picks Updates Backed By Experts - jammulinksnews.com

Advanced Charts

Top Gainers

Top Losers